Xstrahl & SmART Scientific Solutions to showcase two new software solutions for radiation research at ICRR in Montréal, Canada
Xstrahl will demonstrate SmART-RAD and SmART-Contour at the 17th International Congress for Radiation Research (ICRR) August 27-30
Radiant™ Aura Receives U.S. Food and Drug Administration (FDA) 510(k) Clearance
Expands office-based treatment options for millions of non-melanoma skin cancer (NMSC) patients
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, announced its Radiant™ Aura treatment solution has received U.S. Food and Drug Administration (FDA) 510(k) clearance. With advanced features for expanded clinical use, simplified patient positioning, and additional patient comfort, Radiant Aura brings radiation therapy to NMSC patients in any dermatology office.
In this case, Xstrahl 100 was used to treat a keloid scar on an earlobe that developed from an ear piercing.
Superficial and orthovoltage radiation therapy are used to treat many conditions with great results. See how Dr. Aurelia Klajer-Peres at Eiffelvet in France uses the Xstrahl system for both curative and palliative conditions.
Dr. Sean E. Mazloom, MD, FAAD, from ReJUVA Dermatology, Vein & Skin Cancer Center, Venice, FL has been using the RADiant system to treat both squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) in his practice. Depending on a number of factors specific to each patient, he has treated these conditions with superficial radiation therapy (SRT) and electronic brachytherapy (eBT). Below are two case studies that describe the treatment process and results.
Researchers sought to understand the role of kV treatment in locally advanced and/or metastatic breast cancer in which kV radiotherapy was used as the primary modality or as supportive treatment to linac-based RT to gain local tumor control and improve the patient’s quality of life. See details of the recent study, Kilovoltage radiotherapy as a supportive treatment in locally advanced or metastatic breast cancer – a series of six case reports, and the full report on six cases.
Myrna has a history of multiple skin cancers that were treated with Mohs micrographic surgery. During the last year, Myrna was diagnosed twice with basal cell carcinomas (BCC). Her dermatologist, Dr. John Binhlam of Advanced Skin & Laser Center, in Brentwood, Tennessee recommended superficial radiation therapy (SRT) as an alternative to Mohs surgery based on several factors unique to her. Myrna had SRT treatment delivered with the RADiant system, right in Dr. Binhlam’s office.
Xstrahl Delivers CIX FLASH, the First Commercial X-Ray Based Preclinical FLASH Irradiator CIX FLASH supports translational research into current and expanded FLASH radiotherapy techniques Xstrahl announced today the first delivery of CIX FLASH, the world’s first...
Xstrahl in Action A recent study investigated reduced risk of damage to nearby organs during the treatment of ocular tumours. using our Small Animal Radiation Research Platform (SARRP). Publication Orthovoltage X-ray Minibeam Radiation Therapy for the Treatment of...
Contact Us